RPLP0 and neoplasm: Through in vivo mouse experiments, siRNA interference, and ELISA, we demonstrated that RPLP0 knockdown in tumors and anti-PD-1 combinational treatment remarkably inhibited tumor growth and improved anti-tumor immunity.